Document is current
Any future updates will be listed below
-
Authors
Laminou, Ibrahim M.
Issa, Ibrahima
Adehossi, Eric
Maman, Kabirou
Jackou, Hadiza
Coulibaly, Eric
Tohon, Zilahatou B.
Ahmed, Jehan
Sanoussi, Elisha
Koko, Daniel
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05070520 at ClinicalTrials.govDocuments that mention this clinical trial
Therapeutic efficacy and tolerability of artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020
https://doi.org/10.1186/s12936-024-04945-8
-
Funding
Funding for this research was provided by:
U.S. President’s Malaria Initiative
- License Information
-
More Information
Article History
Received: 10 January 2024
Accepted: 12 April 2024
First Online: 13 May 2024
Declarations
:
: This study has received approval from the Ministry of Public Health Ethics Advisory Committee for Health by letter with reference No. 033/2020/CNERS. The Population Services International Research Ethics Committee determined that the activity was public health surveillance. All patients enrolled in the study provided their free and informed consent. For minors, informed consent was obtained from the patient’s parent or legal guardian. The consent forms were dated and signed by both parties. The data collected was kept anonymous and confidential.
: Not applicable.
: The authors declare that they have no competing interests.
